title: Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia.
authors.forename: Philippa L
authors.initials: PL
authors.lastname: Roddam
authors.forename: James M
authors.initials: JM
authors.lastname: Allan
authors.forename: Sara
authors.initials: S
authors.lastname: Rollinson
authors.forename: Alexandra G
authors.initials: AG
authors.lastname: Smith
authors.forename: Eleanor V
authors.initials: EV
authors.lastname: Willett
authors.forename: David
authors.initials: D
authors.lastname: Swirsky
authors.forename: Eve
authors.initials: E
authors.lastname: Roman
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000208:Acute Disease; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology* / Q000378:metabolism; D011110:Polymorphism, Genetic; D011878:Radiotherapy / Q000009:adverse effects; D059005:Topoisomerase II Inhibitors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D059005:Topoisomerase II Inhibitors; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019389:Cytochrome P-450 CYP2D6